Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01159067 · ClinicalTrials.gov registry record · Phase 2
Deferasirox for Treating Patients Who Have Undergone Allogeneic Stem Cell Transplant and Have Iron Overload
A Phase 2 study, sponsored by City of Hope Medical Center.
- Terminated
- Registry status
- Phase 2
- Development phase
- 1
- Enrollment target
NCT01159067 is a Phase 2 study that was terminated before completion, run by City of Hope Medical Center. The registered enrollment target is 1 participants.
The verdict
NCT01159067, a Phase 2 study, was terminated before completion, sponsored by City of Hope Medical Center.
- TERMINATED
- Registry status
- Phase 2
- Development phase
- 1 participants
- Enrollment target
Study Summary
RATIONALE: Low dose deferasirox may be safe and effective in treating patients who have undergone hematopoietic stem cell transplant and have iron overload. PURPOSE: This pilot clinical trial studies safety and tolerability of deferasirox in hematopoietic stem cell transplant recipients who have iron overload. Effect of low dose deferasirox on labile plasma iron is also examined.
Interventions
- DRUG deferasirox
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 1 participants |
| Start Date | 2010-07 |
| Est. Completion | 2011-08-09 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01159067
The ClinicalTrials.gov registry entry for NCT01159067 describes a study currently listed as terminated, categorized as Phase 2. The registered enrollment target is 1 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is City of Hope Medical Center, which has 582 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which deferasirox is the first listed.
NCT01159067 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01159067 about?
NCT01159067 is a clinical study titled "Deferasirox for Treating Patients Who Have Undergone Allogeneic Stem Cell Transplant and Have Iron Overload". RATIONALE: Low dose deferasirox may be safe and effective in treating patients who have undergone hematopoietic stem cell transplant and have iron overload. PURPOSE: This pilot clinical trial studies safety and tolerability of deferasirox in hematopoietic stem cell transplant recipients who have ir...
What is the current status of trial NCT01159067?
This trial is currently terminated. It is a Phase 2 study. The enrollment target is 1 participants. The study started on 2010-07. Estimated completion is 2011-08-09.
What interventions are being tested in trial NCT01159067?
The interventions under investigation include: deferasirox (DRUG).
Who is sponsoring clinical trial NCT01159067?
This trial is sponsored by City of Hope Medical Center, which has 582 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.